Scholars Central

Conference abstractPublished 15 Oct 2013

Discovery of highly-potent and selective inhibitors for the ABCG2 transporter

Authors: Ahcène Boumendjel

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Overexpression of multidrug ABC transporters in cancer cells alters anticancer drugs efficacy by reducing their accumulation in the intracellular compartment. One of the three ABC transporters being largely involved in resistance of cancer cells toward treatments is the breast cancer resistance protein (BCRP/ABCG2). Overcoming multidrug resistance (MDR phenotype) against anticancer drugs is a challenging problem. One of the strategies to overcome MDR can be achieved through effective inhibitors of the multidrug ABC transporters involved in the MDR. In the present communication we will shed light on our recent discovery of highly potent, non-toxic and selective inhibitors of ABCG2 transporter. A special focus will be made on 5-(4-bromobenzyloxy)-2-(2-(5-methoxyindolyl) ethyl-1-carbonyl)-4H-chromen-4-one, namely MBL-II-141. The latter inhibits ABCG2 with high affinity (IC50=0.11 μM) with very low cytotoxicity, giving a markedly high therapeutic index. MBL-II-141 is highly selective for ABCG2 versus other transporters and constitutes a good candidate for in vivo chemosensitization of tumors. The design, synthesis, in vitro and our latest in vivo studies will be presented.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Medicinal Chemistry.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedicinal Chemistry
  • SubjectChemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Ahcène Boumendjel”